First patient successfully dosed in QBiotics’ Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for...
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligo Top-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) — Dermavant Sciences, a dermatology-focused...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its...
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled...
TrialScope, in conjunction with EMD Serono, has launched a new clinical trials website. The site is designed to inform the public and healthcare professionals about clinical trials in general and provide details on EMD Serono clinical trials. EMD Serono Clinical...
BOTHELL, Wash., and TOKYO, Dec. 2, 2019 /PRNewswire/ — Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck,...
Email
Text